ID   AT-MS-1
AC   CVCL_W198
DR   Wikidata; Q54750831
RX   PubMed=3572602;
RX   PubMed=3761063;
CC   Population: Japanese.
CC   Doubling time: ~43 hours (PubMed=3761063).
CC   Derived from site: In situ; Nose, nasal cavity, maxillary sinus; UBERON=UBERON_0001764.
DI   NCIt; C6064; Maxillary sinus squamous cell carcinoma
DI   ORDO; Orphanet_500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 29-06-23; Version: 11
//
RX   PubMed=3572602; DOI=10.3950/jibiinkoka.90.28;
RA   Kumai, Megumi
RA   Takahashi, Mitsuaki
RA   Kanai, Naoki
RA   Unno, Tokuji
RT   "Effects of anti-cancer drugs to permanent human maxillary sinus
RT   carcinoma cell line by DNA analysis using flow cytometry.";
RL   Nihon Jibiinkoka Gakkai Kaiho 90:28-34(1987).
//
RX   PubMed=3761063; DOI=10.3950/jibiinkoka.89.699;
RA   Takahashi, Mitsuaki
RT   "Establishment of a permanent human maxillary sinus carcinoma cell
RT   line and generation of a monoclonal antibody reactive with maxillary
RT   sinus carcinoma.";
RL   Nihon Jibiinkoka Gakkai Kaiho 89:699-705(1986).
//